BACKGROUND: Community acquired respiratory virus (CARV) infections in lung transplant recipients (LTR) have been associated with adverse outcomes, including acute rejection (AR) and decline in allograft function, in some but not in all studies. METHODS: Spirometry and transbronchial biopsy results of LTR diagnosed with CARV infection over a two-yr period were extracted from clinical records. Primary outcomes, studied at 1-2.5 months postinfection, were as follows: (i) incidence of biopsy-proven AR (grade >A0) and (ii) allograft function, defined by forced expiratory volume in one s (FEV(1)). A reference group of biopsies (n = 526) collected during the study period established the baseline incidence of AR. Rhinovirus (RV) and non-rhinovirus (non-RV) infections were analyzed as subgroups. RESULTS: Eighty-seven cases of CARV infection were identified in 59 subjects. Incidences of AR were similar in the post-CARV and reference groups and did not differ significantly after RV vs. non-RV infection. Allograft function declined significantly after non-RV infection, but not after RV infection. CONCLUSIONS: In LTR, CARV infections other than RV are associated with allograft dysfunction at 1-2.5 months after infection. However, CARVs do not appear associated with AR at this time point. The impact of specific CARVs on lung allografts, including the development of chronic allograft rejection, merits further study.
BACKGROUND: Community acquired respiratory virus (CARV) infections in lung transplant recipients (LTR) have been associated with adverse outcomes, including acute rejection (AR) and decline in allograft function, in some but not in all studies. METHODS: Spirometry and transbronchial biopsy results of LTR diagnosed with CARV infection over a two-yr period were extracted from clinical records. Primary outcomes, studied at 1-2.5 months postinfection, were as follows: (i) incidence of biopsy-proven AR (grade >A0) and (ii) allograft function, defined by forced expiratory volume in one s (FEV(1)). A reference group of biopsies (n = 526) collected during the study period established the baseline incidence of AR. Rhinovirus (RV) and non-rhinovirus (non-RV) infections were analyzed as subgroups. RESULTS: Eighty-seven cases of CARV infection were identified in 59 subjects. Incidences of AR were similar in the post-CARV and reference groups and did not differ significantly after RV vs. non-RV infection. Allograft function declined significantly after non-RV infection, but not after RV infection. CONCLUSIONS: In LTR, CARV infections other than RV are associated with allograft dysfunction at 1-2.5 months after infection. However, CARVs do not appear associated with AR at this time point. The impact of specific CARVs on lung allografts, including the development of chronic allograft rejection, merits further study.
Authors: S S Weigt; A Derhovanessian; E Liao; S Hu; A L Gregson; B M Kubak; R Saggar; R Saggar; V Plachevskiy; M C Fishbein; J P Lynch; A Ardehali; D J Ross; H-J Wang; R M Elashoff; J A Belperio Journal: Am J Transplant Date: 2011-12-07 Impact factor: 8.086
Authors: Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Jens Gottlieb; Thomas F Schulz; Tobias Welte; Thomas Fuehner; Martin Dierich; Andre R Simon; Ilka Engelmann Journal: Transplantation Date: 2009-05-27 Impact factor: 4.939
Authors: Paul R Allyn; Erin L Duffy; Romney M Humphries; Patil Injean; S Samuel Weigt; Rajan Saggar; Michael Y Shino; Joseph P Lynch; Abbas Ardehali; Bernard Kubak; Chi-Hong Tseng; John A Belperio; David J Ross; Aric L Gregson Journal: Transplantation Date: 2016-11 Impact factor: 4.939
Authors: Katrina Bazemore; Michael Rohly; Nitipong Permpalung; Kai Yu; Irina Timofte; A Whitney Brown; Jonathan Orens; Aldo Iacono; Steven D Nathan; Robin K Avery; Hannah Valantine; Sean Agbor-Enoh; Pali D Shah Journal: J Heart Lung Transplant Date: 2021-05-30 Impact factor: 10.247
Authors: Jonathan Hoover; Michelle A Mintz; Fred Deiter; Emily Aminian; Joy Chen; Steven R Hays; Jonathan P Singer; Daniel R Calabrese; Jasleen Kukreja; John R Greenland Journal: Transpl Infect Dis Date: 2021-02-18
Authors: Dagmara W Lewandowska; Peter W Schreiber; Macé M Schuurmans; Bettina Ruehe; Osvaldo Zagordi; Cornelia Bayard; Michael Greiner; Fabienne D Geissberger; Riccarda Capaul; Andrea Zbinden; Jürg Böni; Christian Benden; Nicolas J Mueller; Alexandra Trkola; Michael Huber Journal: PLoS One Date: 2017-05-23 Impact factor: 3.240
Authors: M Peghin; H H Hirsch; Ó Len; G Codina; C Berastegui; B Sáez; J Solé; E Cabral; A Solé; F Zurbano; F López-Medrano; A Román; J Gavaldá Journal: Am J Transplant Date: 2016-10-14 Impact factor: 8.086